Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: elie fried who wrote (2672)	8/20/1998 10:03:00 AM
From: Bruce Rozenblit	Read Replies (1) \| Respond to of 3725

No technology is ever 100% proprietary and there are always competing technologies. Competition breeds customer awareness and validates new techniques. One of the marketing problems Imat has had is convincing the world that calcium scoring is an accurate and valid gauge of heart disease. Now it looks like the rest of the world is starting to wake up and smell the roses. Secondly, the managed care establishment has been and is highly resistant towards preventive diagnostic tests. The more that are available should help to push the insurance companies to use these procedures.